B-Cell Acute Lymphoblastic Leukemia, Adult
9
1
3
2
Key Insights
Highlights
Success Rate
100% trial completion (above average)
Clinical Risk Assessment
Based on trial outcomes
Moderate Risk
Score: 37/100
0.0%
0 terminated out of 9 trials
100.0%
+13.5% vs benchmark
0%
0 trials in Phase 3/4
50%
1 of 2 completed with results
Key Signals
Data Visualizations
Phase Distribution
Trial Status
Trial Success Rate
Benchmark: 86.5%
Based on 2 completed trials
Clinical Trials (9)
A Study of Inotuzumab and Blinatumomab in People With B-cell Acute Lymphoblastic Leukemia
Autologous Bedside CD19 CAR T-cell Therapy for B-ALL
Allogeneic UCB-derived CAR-T for B-ALL
Blinatumomab & Pembrolizumab for Adults With Relapsed/Refractory B-cell ALL With High Marrow Lymphoblasts
Blinatumomab Combined With Venetoclax as Maintenance Therapy After Allo-HSCT in High-risk Ph Negative Acute B-cell Lymphoblastic Leukemia
Allogeneic CD19-targeted CAR-γδT Cell Infusion Therapy in Relapsed/Refractory B Cell Acute Lymphoblastic Leukemia
Sequential CD19 and CD22 CAR-T Therapy for Newly Diagnosed Ph+ B-ALL
CD19 Chimeric Antigen Receptor (CAR) T Cells for Adults With Recurrent or Refractory B Cell Malignancies
Sequential CD19 and CD22 CAR-T Therapy for Newly Diagnosed Ph- B-ALL